StreetInsider.com News Articles

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences

Tue, 08 Sep 2026 08:00:00 -0400

VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (Nasdaq: EPRX) (TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced today that its common shares have commenced trading on the Nasdaq Global Select Market. The Company also announced that members of its management team will participate in upcoming investor conferences.

The Company’s common shares were previously listed on the Nasdaq Capital Market and will continue to trade under the ticker symbol “EPRX.”

Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences

Tue, 08 Sep 2026 08:00:00 -0400

The Company’s common shares were previously listed on the Nasdaq Capital Market and will continue to trade under the ticker symbol “EPRX.”

Form EFFECT EUPRAXIA PHARMACEUTICALS

Tue, 25 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260825/26970336.html

Form EFFECT EUPRAXIA PHARMACEUTICALS

Tue, 25 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260825/26970336.html

Form F-10/A EUPRAXIA PHARMACEUTICALS

Wed, 19 Aug 2026 15:35:00 -0400

si-local-file:///var/storage/secattach/20260819/26949791.html

Form F-10/A EUPRAXIA PHARMACEUTICALS

Wed, 19 Aug 2026 15:35:00 -0400

si-local-file:///var/storage/secattach/20260819/26949791.html

Form SCHEDULE 13G/A EUPRAXIA PHARMACEUTICALS Filed by: MANCHESTER MANAGEMENT CO LLC

Thu, 13 Aug 2026 13:03:00 -0400

si-local-file:///var/storage/secattach/20260813/26919414.html

Form SCHEDULE 13G/A EUPRAXIA PHARMACEUTICALS Filed by: MANCHESTER MANAGEMENT CO LLC

Thu, 13 Aug 2026 13:03:00 -0400

si-local-file:///var/storage/secattach/20260813/26919414.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: Aug 13

Thu, 13 Aug 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260813/26916948.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: Aug 13

Thu, 13 Aug 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260813/26916948.html

Eupraxia reports swallowing symptom data from EoE drug trial

Thu, 13 Aug 2026 08:00:33 -0400

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, TSX: EPRX) released new data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI in patients with eosinophilic esophagitis (EoE), including the first analysis of the drug's effect on odynophagia, or pain when swallowing.

In the cohorts analyzed (Cohorts 7-9), 62% of patients reported moderate to severe odynophagia at baseline. That figure fell to 25% at the 24- and 52-week timepoints. Separately, 23% of patients reported severe odynophagia at baseline, while no patients reported severe odynophagia at either the 24- or 52-week mark.

On dysphagia, or difficulty swallowing, 77% of patients in the same cohorts reported moderate

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients

Thu, 13 Aug 2026 08:00:00 -0400

The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post treatment
In the same analysis, 23% of patients reported severe odynophagia at baseline; and no patients reported severe odynophagia at the 24 and 52 weeks timepoints
The number of patients experiencing moderate to severe dysphagia (difficulty swallowing) in Cohorts 7-9 was reduced from 77% at baseline to 25% at 24 and 52 weeks post treatment
At baseline 31% of patients in Cohorts 7-9 had severe

Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients

Thu, 13 Aug 2026 08:00:00 -0400

The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post treatment
In the same analysis, 23% of patients reported severe odynophagia at baseline; and no patients reported severe odynophagia at the 24 and 52 weeks timepoints
The number of patients experiencing moderate to severe dysphagia (difficulty swallowing) in Cohorts 7-9 was reduced from 77% at baseline to 25% at 24 and 52 weeks post treatment
At baseline 31% of patients in Cohorts 7-9 had severe

Form 6-K EUPRAXIA PHARMACEUTICALS For: Aug 11

Tue, 11 Aug 2026 17:24:00 -0400
si-local-file:///var/storage/secattach/20260811/26907164.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: Aug 11

Tue, 11 Aug 2026 17:24:00 -0400
si-local-file:///var/storage/secattach/20260811/26907164.html

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 17:21:00 -0400

New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI

Strengthened executive team and board to bolster late-stage drug development and global commercialization capabilities.

VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2026. All dollar values are in U.S. dollars unless

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 17:21:00 -0400

New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI

Strengthened executive team and board to bolster late-stage drug development and global commercialization capabilities.

VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2026. All dollar values are in U.S. dollars unless

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 17:21:00 -0400

New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI

Strengthened executive team and board to bolster late-stage drug development and global commercialization capabilities.

VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2026. All dollar values are in U.S. dollars unless

Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 17:21:00 -0400

New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI

Strengthened executive team and board to bolster late-stage drug development and global commercialization capabilities.

VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2026. All dollar values are in U.S. dollars unless

Form F-X EUPRAXIA PHARMACEUTICALS Filed by: EUPRAXIA PHARMACEUTICALS INC.

Thu, 06 Aug 2026 06:06:00 -0400
si-local-file:///var/storage/secattach/20260806/26877563.html

Form F-X EUPRAXIA PHARMACEUTICALS Filed by: EUPRAXIA PHARMACEUTICALS INC.

Thu, 06 Aug 2026 06:06:00 -0400
si-local-file:///var/storage/secattach/20260806/26877563.html

Form F-10 EUPRAXIA PHARMACEUTICALS

Thu, 06 Aug 2026 06:05:00 -0400
si-local-file:///var/storage/secattach/20260806/26877530.html

Form F-10 EUPRAXIA PHARMACEUTICALS

Thu, 06 Aug 2026 06:05:00 -0400
si-local-file:///var/storage/secattach/20260806/26877530.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: Jul 15

Wed, 15 Jul 2026 13:26:00 -0400
si-local-file:///var/storage/secattach/20260715/26773414.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: Jul 15

Wed, 15 Jul 2026 13:26:00 -0400
si-local-file:///var/storage/secattach/20260715/26773414.html